Skip to main content

Table 4 Diagnostic performance of prediction models for ALK mutation status in the training and validation sets 1–3

From: Intratumoral and peritumoral CT radiomics in predicting anaplastic lymphoma kinase mutations and survival in patients with lung adenocarcinoma: a multicenter study

Models

Cohorts

AUC (95% CI)

Sensitivity (%) (95% CI)

Specificity (%) (95% CI)

Accuracy (%) (95% CI)

PPV (%) (95% CI)

NPV (%)

(95% CI)

Clinical

Training set

0.690

(0.611–0.761)

74.29 (26/35)

(59.81–88.77)

55.37 (67/121)

(46.51–64.23)

59.62 (93/156)

(51.92–67.32)

32.50 (26/80)

(22.24–42.76)

88.16 (67/76)

(80.89–95.42)

 

Validation set 1

0.648

(0.543–0.745)

56.52 (13/23)

(36.81–74.37)

70.00 (49/70)

(59.36–80.74)

66.67 (62/93)

(57.09–76.25)

38.24 (13/34)

(21.90-54.57)

83.05 (49/59)

(73.48–92.62)

 

Validation set 2

0.634

(0.548–0.714)

68.00 (17/25)

(48.41–82.79)

51.75 (59/114)

(42.58–60.93)

54.68 (76/139)

(46.40-62.95)

23.61 (17/72)

(13.80-33.42)

88.06 (59/67)

(80.30-95.82)

 

Validation set 3

0.663

(0.570–748)

79.17 (19/24)

(59.93–90.76)

58.06 (54/93)

(48.04–68.10)

62.39 (73/117)

(52.36–71.17)

32.76 (19/58)

(20.68–44.84)

91.53 (54/59)

(84.42–98.63)

GPTV3 Radiomics

Training set

0.912

(0.855–0.951)

85.71 (30/35)

(74.12–97.31)

85.12 (103/121)

(78.78–91.46)

85.26 (133/156)

(79.69–90.82)

62.50 (30/48)

(48.80–76.20)

95.37 (103/108)

(48.80–76.20)

 

Validation set 1

0.822

(0.729–0.894)

86.96 (20/23)

(67.87–95.46)

71.43 (50/70)

(60.85–82.01)

75.27 (70/93)

(66.50-84.04)

50.00 (20/40)

(34.50–65.50)

94.34 (50/53)

(84.63–98.06)

 

Validation set 2

0.841

(0.769–0.897)

76.00 (19/25)

(59.26–92.74)

84.21 (96/114)

(77.52–90.90)

82.73 (115/139)

(76.45–89.20)

51.35 (19/37)

(35.25–67.46)

94.12 (96/102)

(89.55–98.68)

 

Validation set 3

0.771

(0.685–0.844)

75.00 (18/24)

(57.68–92.32)

73.12 (68/93)

(64.11–82.31)

73.50 (86/117)

(65.51–81.50)

41.86 (18/43)

(27.11–56.61)

91.89 (68/74)

(85.67–98.11)

Nomogram

Training set

0.951

(0.904–0.979)

85.71 (30/35)

(74.21–97.31)

92.56 (112/121)

(88.05–97.56)

91.03 (142/156)

(87.51–95.45)

76.92 (30/39)

(62.50-88.39)

95.73 (112/117)

(92.81–98.49)

 

Validation set 1

0.855

(0.766–0.919)

78.26 (18/23)

(61.40-95.12)

87.14 (61/70)

(77.96–94.74)

84.95 (79/93)

(76.13–91.52)

66.67 (18/27)

(47.82–84.35)

92.42 (61/66)

(86.33–97.77)

 

Validation set 2

0.882

(0.801–0.962)

76.00 (19/25)

(56.57–88.50)

92.98 (106/114)

(87.65–97.46)

89.93 (125/139)

(85.81–92.56)

70.37 (19/27)

(52.82–86.82)

94.64 (106/112)

(89.20-98.07)

 

Validation set 3

0.810

(0.727–0.877)

70.83 (17/24)

(50.83–85.09)

79.57 (74/93)

(71.24–86.46)

77.78 (91/117)

(69.63–85.45)

47.22 (17/36)

(30.45–61.83)

91.36 (74/81)

(84.99–97.13)

  1. Abbreviations: ALK, anaplastic lymphoma kinase; AUC, area under the curve; CI, confidence interval; GPTV, gross peritumoral tumor volume; NPV, negative predictive value; PPV, positive predictive value